Trial Profile
A Randomised, Double-blind, Placebo-controlled, 4-period Crossover Study to Evaluate Next Day Effects of MK-4305 on Driving Performance in Healthy Elderly Subjects.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Dec 2017
Price :
$35
*
At a glance
- Drugs Suvorexant (Primary)
- Indications Insomnia
- Focus Pharmacodynamics
- Sponsors Merck & Co
- 15 Dec 2017 New trial record